Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Roche Plans Biotech Plants

June 28, 2004 | A version of this story appeared in Volume 82, Issue 26

Roche will expand its capacity for biotechnology products through a new biotech center at its Basel headquarters and a new plant in Penzberg, Germany. Each project will cost about $300 million and will take three years to complete, the company says. Roche will tear down an existing chemical production building to make room for the Basel center. The new facilities will be used to produce monoclonal antibodies for the anticancer medicines Avastin (bevacizumab) and Herceptin (trastuzumab). Some 150 new jobs will be created at each site.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.